

Acceleration of Human Papillomavirus Vaccine Introduction in Indonesia: a Policy Analysis

AUTHORS: Hashta Meyta, Prima Yosephine, Gertrudis Tandy, Devi Anisiska, Lili Nur Indah Sari, Septianita

Introduction

Indonesia has rapidly accelerated the Human Papillomavirus Vaccine (HPV) expansion from a concentrated 20 districts between 2016 and 2021 to a nationwide scale-up in 2023. The national rollout in 514 districts is initially scheduled for 2024 and has been accelerated as an intervention to eliminate cervical cancer by 2030

Methods

We used a health policy triangle analytical framework. We conducted a desk review of country policy documents, the Government's website, and social media to examine HPV vaccination policies issued between 1 January 2019 and 9 August 2023

Results

The country developed supporting policies involving many actors, including national and international stakeholders. A major policy improvement was a joint decree from four ministries. The HPV policy development has grown over the years, starting from the introduction stages and reaching out-of-school strategies. The policies were developed in the context of disease prioritization, technical assistance support, and growing awareness of vaccination.



The policy process aimed to adopt regulations for the rollout of the vaccine introduction aligned with the government agenda setting including strengthening health system digitalization; encouraging using domestic vaccines which finally attracts technology transfer between external producer and national vaccine manufacturer.

Conclusions

The evolution of HPV vaccination nationwide has been marked by scientific advancement, domestic vaccine development, and intersectoral collaboration in promoting public health. The lesson learned from the policy development process was that comprehensive approach is crucial to support success in accelerating the introduction. However, potential changes in the government structure and political situation need to be anticipated.

Keywords: Health Policy, Policy Framework, HPV Vaccination

Acknowledgments

